Table 3.
Aptamers used in traceable clinical trials.
| NCT number | Target (aptamer + adjuvant) | Conditions | Phase/s | Funded by |
|---|---|---|---|---|
| NCT00950638 | C5 complement (ARC1905 aptamer) | AMD | 1 | Industry |
| NCT00709527 | C5 complement (ARC1905 aptamer + Lucentis) | AMD | 1 | Industry |
| NCT01089517 | PDGF (E10030 aptamer + Lucentis) | AMD | 2 | Industry |
| NCT00569140 | PDGF (E10030 aptamer) | AMD | 1 | Industry |
| NCT00312351 | VEGF (Macugen) | Macular Degeneration | 4 | Industry |
| NCT00021736 | VEGF | AMD and Choroidal Neovascularization | 2/3 | Industry |
| NCT00215670 | VEGF (Macugen) | AMD | 2/3 | Industry |
| NCT00321997 | VEGF (Macugen) | AMD | 2/3 | Industry |
| NCT00040313 | VEGF (Macugen) | DME | 2 | Industry |
| NCT01487070 | VEGF (Macugen) | Proliferative Diabetic Retinopathy | 1 | Other |
| NCT01487044 | VEGF (Macugen) | DME | Other/Industry | |
| NCT00632242 | vWF (ARC1779) | Purpura Thrombotic, Thrombocytopenic von Willebrand Disease Type-2b | 2 | Industry |
| NCT01034410 | Nucleolin (AS1411) | Acute Myeloid Leukemia | 2 | Industry |
| NCT01191372 | BAX499 (ARC19499) | Hemophilia | 1/2 | Industry |
| NCT01194934 | CXCL12/SDF-1 (NOX-A12) | Hematopoietic Stem Cell Transplantation | 1 | Industry |
| NCT00976378 | CXCL12/SDF-1 (NOX-A12) | Autologous Stem Cell Transplantation | 1 | Industry/Other |
| NCT00976729 | CCL2/MCP-1 (NOX-E36) | Chronic Inflammatory Diseases Type 2 Diabetes Mellitus Systemic Lupus Erythematosus | 1 | Industry |
| NCT00113997 | REG1 | Healthy | 1 | NIH |
| NCT00056199 | von Hippel-Lindau Disease | 1 | NIH |